{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:36:42Z","timestamp":1773391002272,"version":"3.50.1"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"S20","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Proc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The fourteenth annual ASCAT conference was held 21\u201323 October 2019. The theme of the conference was \u2018Sickle Cell and Thalassaemia disorders new treatment horizon; while ensuring patient safety and delivering excellence in routine patient care.\u2019 Over the three-day conference, topics on current and novel models of care, advances in bone marrow transplant and gene therapy, as well as the psychosocial aspects of mind, body and health related quality of life were discussed. In addition, blood transfusion, apheresis, iron chelation therapy and acute haemolytic complications were presented. Quality standards in the diagnosis and treatment of sickle cell and thalassaemia were reviewed. Experts from Europe, the United Kingdom, the Middle East, the United States and Africa reported up-to-date scientific data, guides to comprehensive care, and current research into developing cures and advancing current therapy were described. In addition, oral and poster presentations on novel research from all over the world were shown during the conference.<\/jats:p>","DOI":"10.1186\/s12919-020-00204-1","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:07:55Z","timestamp":1608077275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings"],"prefix":"10.1186","volume":"14","author":[{"given":"Crawford","family":"Strunk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Colombatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biree","family":"Andemariam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kesse-Adu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baba P. D.","family":"Inusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"issue":"2","key":"204_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/bjh.16504","volume":"190","author":"A Nardo-Marino","year":"2020","unstructured":"Nardo-Marino A, Brousse V, Rees D. Emerging therapies in sickle cell disease. Br J Haematol. 2020;190(2):149\u201372. https:\/\/doi.org\/10.1111\/bjh.16504 Epub 2020 Mar 6.","journal-title":"Br J Haematol"},{"key":"204_CR2","doi-asserted-by":"publisher","unstructured":"Ali MA, Ahmad A, Chaudry H, Aiman W, Aamir S, Anwar MY, Khan A. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;S0301-472X(20):30356-8. https:\/\/doi.org\/10.1016\/j.exphem.2020.08.008.","DOI":"10.1016\/j.exphem.2020.08.008"},{"key":"204_CR3","doi-asserted-by":"publisher","unstructured":"Inusa BPD, Colombatti R. European migration crises: The role of national hemoglobinopathy registries in improving patient access to care. Pediatr Blood Cancer. 2017;64(7). https:\/\/doi.org\/10.1002\/pbc.26515.","DOI":"10.1002\/pbc.26515"},{"key":"204_CR4","doi-asserted-by":"crossref","unstructured":"Faro EZ, Shook L, Treadwell MJ, King AA, Whiteman LN, Ivy ED, Hulihan M, Kavanagh PL, Selk S, Oyeku S, Berns SD. A National Measurement Framework to Assess and Improve Sickle Cell Care in 4 US Regions. Public Health Rep. 2020;135(4):442\u2013451.","DOI":"10.1177\/0033354920935068"}],"container-title":["BMC Proceedings"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-020-00204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12919-020-00204-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-020-00204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:34:19Z","timestamp":1608078859000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcproc.biomedcentral.com\/articles\/10.1186\/s12919-020-00204-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":4,"journal-issue":{"issue":"S20","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1186\/s12919-020-00204-1","relation":{},"ISSN":["1753-6561"],"issn-type":[{"value":"1753-6561","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A Campbell: research funding and consultancy from Global Blood Therapeutics (GBT), Novartis; and consultancy for Bluebird Bio; B Andemariam: consultancy for Bluebird Bio, CRISPR\/Vertex, Novartis, NovoNordisk, Roche, Cyclerion, Terumo, Sanofi; DSMB: Global Blood Therapeutics; research funding: Imara; B Inusa: education funding: Novartis, AstraZeneca, Global Blood Therapeutics, Celgene, Vertex;  ARISE declaration: This project has received funding from the European Union Horizon 2020 Research and Innovation Programme under Marie-Sklowdowska Curie Agreement, No 824021\u00a0ARISE project C. Strunk: consultancy Global Blood Therapeutics, Novartis and Medunik USA\u00a0and Forma Therapeutics; R Colombatti: research funding: Global Blood Therapeutics, Novartis. No disclosures to declare from the other co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}